A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Public ClinicalTrials.gov record NCT05084508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Varicella Vaccine at Various Potencies Compared With Varivax, as a First Dose, Administered in Healthy Children in Their Second Year of Life
Study identification
- NCT ID
- NCT05084508
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 800 participants
Conditions and interventions
Conditions
Interventions
- Investigational varicella vaccine low potency Biological
- Investigational varicella vaccine medium potency Biological
- Investigational varicella vaccine high potency Biological
- Licensed varicella vaccine Lot 1 Biological
- Licensed varicella vaccine Lot 2 Biological
- Measles, mumps, and rubella vaccine Biological
- Hepatitis A vaccine Biological
- 13-valent pneumococcal conjugate vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Months to 15 Months
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2022
- Primary completion
- Feb 8, 2024
- Completion
- Jun 12, 2024
- Last update posted
- Feb 27, 2025
2022 – 2024
United States locations
- U.S. sites
- 41
- U.S. states
- 20
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Bryant | Arkansas | 72022 | — |
| GSK Investigational Site | Jonesboro | Arkansas | 72401 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72202 | — |
| GSK Investigational Site | Bellflower | California | 90706 | — |
| GSK Investigational Site | Downey | California | 90240 | — |
| GSK Investigational Site | Foothill Ranch | California | 92610 | — |
| GSK Investigational Site | Huntington Park | California | 90255 | — |
| GSK Investigational Site | Los Angeles | California | 90057 | — |
| GSK Investigational Site | West Covina | California | 91790 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Atlanta | Georgia | 30310 | — |
| GSK Investigational Site | Idaho Falls | Idaho | 83404 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70006-5322 | — |
| GSK Investigational Site | Gulfport | Mississippi | 39507 | — |
| GSK Investigational Site | Bridgeton | Missouri | 63044 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Omaha | Nebraska | 68198 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89128 | — |
| GSK Investigational Site | East Syracuse | New York | 13210 | — |
| GSK Investigational Site | The Bronx | New York | 10468 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28203 | — |
| GSK Investigational Site | Cleveland | Ohio | 44121 | — |
| GSK Investigational Site | Dayton | Ohio | 45406 | — |
| GSK Investigational Site | Fort Washington | Pennsylvania | 19034 | — |
| GSK Investigational Site | Barnwell | South Carolina | 29812 | — |
| GSK Investigational Site | Tullahoma | Tennessee | 37388 | — |
| GSK Investigational Site | Corpus Christi | Texas | 78414 | — |
| GSK Investigational Site | Dallas | Texas | 75230-2571 | — |
| GSK Investigational Site | Dickinson | Texas | 77539 | — |
| GSK Investigational Site | Houston | Texas | 77087 | — |
| GSK Investigational Site | McAllen | Texas | 78504 | — |
| GSK Investigational Site | Pflugerville | Texas | 78660 | — |
| GSK Investigational Site | San Antonio | Texas | 78218 | — |
| GSK Investigational Site | Layton | Utah | 84041 | — |
| GSK Investigational Site | Provo | Utah | 84604 | — |
| GSK Investigational Site | Roy | Utah | 84067 | — |
| GSK Investigational Site | South Jordan | Utah | 84095 | — |
| GSK Investigational Site | St. George | Utah | 84790 | — |
| GSK Investigational Site | Syracuse | Utah | 84075 | — |
| GSK Investigational Site | Charlottesville | Virginia | 22902 | — |
| GSK Investigational Site | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05084508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05084508 live on ClinicalTrials.gov.